NEW YORK, June 15th, 2015 – Tavec Pharmaceuticals, Inc. (Tavec) announced today that it has secured $850,000 in seed funding to complete key pre-clinical validation studies and further development of intellectual property. Tavec’s exosome mediated technology enables the delivery by ...
Read More »